Showing 1 to 12 of 42 results
FDA Approves First Clinical Trial for Genetically Modified Pig Organs
The FDA has approved the first clinical trial for genetically modified pig kidneys for human use, following successful cases of xenotransplantation, aiming to alleviate the critical organ shortage.
FDA Approves First Clinical Trial for Genetically Modified Pig Organs
The FDA has approved the first clinical trial for genetically modified pig kidneys for human use, following successful cases of xenotransplantation, aiming to alleviate the critical organ shortage.
Progress
48% Bias Score
Successful Pig-to-Human Lung Transplant Achieved
Chinese surgeons successfully transplanted a genetically modified pig lung into a brain-dead human, maintaining its viability for nine days before immune rejection; this pioneering study, published in Nature Medicine, demonstrates progress in xenotransplantation to address organ shortages.
Successful Pig-to-Human Lung Transplant Achieved
Chinese surgeons successfully transplanted a genetically modified pig lung into a brain-dead human, maintaining its viability for nine days before immune rejection; this pioneering study, published in Nature Medicine, demonstrates progress in xenotransplantation to address organ shortages.
Progress
40% Bias Score
Private Companies Push Gene Editing of Human Embryos
Fueled by Silicon Valley investment and pronatalist views, private companies are pursuing gene editing of human embryos, aiming to prevent diseases and potentially enhance traits, despite ethical concerns and regulatory restrictions.
Private Companies Push Gene Editing of Human Embryos
Fueled by Silicon Valley investment and pronatalist views, private companies are pursuing gene editing of human embryos, aiming to prevent diseases and potentially enhance traits, despite ethical concerns and regulatory restrictions.
Progress
60% Bias Score
Saxony-Anhalt Farmers Seek EU Approval for New Breeding Techniques to Combat Climate Change
The Saxony-Anhalt Farmers' Association advocates for new breeding methods, particularly new genomic techniques (NGTs), hoping for relaxed EU regulations to combat climate change impacts like droughts and new pests; the EU Commission is currently negotiating potential exemptions for NGT plants, while...
Saxony-Anhalt Farmers Seek EU Approval for New Breeding Techniques to Combat Climate Change
The Saxony-Anhalt Farmers' Association advocates for new breeding methods, particularly new genomic techniques (NGTs), hoping for relaxed EU regulations to combat climate change impacts like droughts and new pests; the EU Commission is currently negotiating potential exemptions for NGT plants, while...
Progress
48% Bias Score
CRISPR Gene Editing Shows Promise in Treating Rare Infant Disorder
A six-month-old American baby with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare genetic disorder affecting approximately one in a million infants, received a custom CRISPR gene-editing therapy resulting in a reduction of medication dependency and improved health.
CRISPR Gene Editing Shows Promise in Treating Rare Infant Disorder
A six-month-old American baby with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare genetic disorder affecting approximately one in a million infants, received a custom CRISPR gene-editing therapy resulting in a reduction of medication dependency and improved health.
Progress
36% Bias Score
Xenotransplantation: Pig Organs Offer Hope in Critical Organ Shortage
CNN's "Dr. Sanjay Gupta Reports: Animal Pharm" on May 18th explores xenotransplantation, using genetically modified pig organs for human transplants to combat the critical organ shortage killing 17 people daily in the US, highlighting patient pioneers' altruism and the ongoing scientific advancement...
Xenotransplantation: Pig Organs Offer Hope in Critical Organ Shortage
CNN's "Dr. Sanjay Gupta Reports: Animal Pharm" on May 18th explores xenotransplantation, using genetically modified pig organs for human transplants to combat the critical organ shortage killing 17 people daily in the US, highlighting patient pioneers' altruism and the ongoing scientific advancement...
Progress
48% Bias Score
FDA Approves First Human Trials of Gene-Edited Pig Kidneys
The FDA has approved the first human clinical trials using gene-edited pig kidneys from eGenesis, offering hope for the over 100,000 people on the organ transplant waiting list.
FDA Approves First Human Trials of Gene-Edited Pig Kidneys
The FDA has approved the first human clinical trials using gene-edited pig kidneys from eGenesis, offering hope for the over 100,000 people on the organ transplant waiting list.
Progress
56% Bias Score
First Successful Pig-to-Human Lung Transplant in China
A 39-year-old brain-dead man in China received a genetically modified pig lung transplant that functioned for nine days before his family requested the experiment's termination; scientists hailed it as a significant step forward in xenotransplantation despite acknowledging ongoing challenges.
First Successful Pig-to-Human Lung Transplant in China
A 39-year-old brain-dead man in China received a genetically modified pig lung transplant that functioned for nine days before his family requested the experiment's termination; scientists hailed it as a significant step forward in xenotransplantation despite acknowledging ongoing challenges.
Progress
40% Bias Score
Human Embryo Gene Editing: Renewed Interest and Ethical Concerns
Silicon Valley startups and pronatalist investors are funding research into gene editing human embryos to prevent diseases and potentially enhance traits, despite ethical concerns following the 2018 creation of CRISPR gene-edited babies in China.
Human Embryo Gene Editing: Renewed Interest and Ethical Concerns
Silicon Valley startups and pronatalist investors are funding research into gene editing human embryos to prevent diseases and potentially enhance traits, despite ethical concerns following the 2018 creation of CRISPR gene-edited babies in China.
Progress
52% Bias Score
CRISPR Therapy Shows Promise but Faces Rollout Challenges
The first CRISPR-based therapy, approved in late 2023, offers a cure for previously untreatable diseases; however, slow rollout due to manufacturing and accreditation challenges highlights the need for regulatory adaptations and technological advancements in CRISPR enzyme delivery.
CRISPR Therapy Shows Promise but Faces Rollout Challenges
The first CRISPR-based therapy, approved in late 2023, offers a cure for previously untreatable diseases; however, slow rollout due to manufacturing and accreditation challenges highlights the need for regulatory adaptations and technological advancements in CRISPR enzyme delivery.
Progress
36% Bias Score
Gene Editing Successfully Treats Baby's Life-Threatening Disorder
Doctors successfully treated a baby born with a life-threatening urea cycle disorder using a custom gene-editing therapy in Philadelphia, marking a major breakthrough in personalized medicine; the therapy appears to be working, allowing the baby to eat more protein, gain weight, and reach developmen...
Gene Editing Successfully Treats Baby's Life-Threatening Disorder
Doctors successfully treated a baby born with a life-threatening urea cycle disorder using a custom gene-editing therapy in Philadelphia, marking a major breakthrough in personalized medicine; the therapy appears to be working, allowing the baby to eat more protein, gain weight, and reach developmen...
Progress
40% Bias Score
Successful Gene Editing Treats Rare Genetic Disease in Baby
A baby with severe CPS1 deficiency, a rare genetic disorder affecting approximately one in a million infants, received a custom gene-editing therapy using CRISPR base editing, resulting in significant health improvements within months, opening possibilities for treating other rare genetic diseases.
Successful Gene Editing Treats Rare Genetic Disease in Baby
A baby with severe CPS1 deficiency, a rare genetic disorder affecting approximately one in a million infants, received a custom gene-editing therapy using CRISPR base editing, resulting in significant health improvements within months, opening possibilities for treating other rare genetic diseases.
Progress
40% Bias Score
Showing 1 to 12 of 42 results